Qiu et al. [11] revealed that Tfh cells enhanced CD19+ B cells releasing TGF-α and IL-10 in NSCLC patients, resulting in further immunosuppression and tumor progression. This evidence concerns the gene IL10 and non-small cell lung carcinoma.